A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

Neurology
J PalaceB Lecky

Abstract

We compared prednisolone (PRED) and azathioprine (AZA) versus prednisolone alone in the treatment of MG. Prednisolone alone or combined with azathioprine is widely used in the treatment of MG, but no randomized placebo-controlled comparative trial data are available. The prednisolone dose and clinical outcome were compared in a multicenter randomized double-blind study of 34 MG patients who were followed up for 3 years. One group (PRED + AZA) received prednisolone (on alternate days) plus azathioprine (2.5 mg/kg); the other group received prednisolone on alternate days plus placebo (PRED + PLAC). Initial high-dose prednisolone (1.5 mg/kg on alternate days) was tapered at remission to the minimal dose required to maintain remission. The prednisolone dose did not differ significantly between the two groups at 1 year (median values: PRED + AZA, 37.5 mg on alternate days; PRED + PLAC, 45 mg on alternate days) but was reduced at 2 and 3 years in the PRED + AZA group (median value at 3 years: PRED + AZA, 0 mg on alternate days; PRED + PLAC, 40 mg on alternate days; p=0.02). Relapses and failures to remit over the 3 years were more frequent in the PRED + PLAC group. There was a sharp rise in the anti-acetylcholine receptor (AChR) tite...Continue Reading

Citations

Jul 13, 2002·Muscle & Nerve·Lucas Gustavo De FeoNéstor A Molfino
Dec 26, 2001·Muscle & Nerve·Michael H Rivner
Apr 19, 2005·Journal of Neurology·Eduardo Nobile-Orazio
May 16, 2008·Journal of Neurology·P GoldsmithN Bhalla
Jun 6, 2007·Current Allergy and Asthma Reports·Stephen Reddel
Mar 20, 2002·Current Neurology and Neuroscience Reports·Emma Ciafaloni, Donald B Sanders
Oct 12, 2010·Current Neurology and Neuroscience Reports·Vikas Kumar, Henry J Kaminski
Feb 5, 2004·Current Treatment Options in Neurology·Michael Graves, Jonathan S. Katz
Dec 22, 2004·Current Treatment Options in Neurology·Vern C Juel, Janice M Massey
Dec 22, 2004·Current Treatment Options in Neurology·Neil C Porter, Brian C Salter
Sep 16, 2010·Current Treatment Options in Neurology·Agnes Jani-Acsadi, Robert P Lisak
Sep 14, 2011·Current Treatment Options in Neurology·Hugh J McMillanPeter B Kang
Nov 21, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ralf Gold, Christiane Schneider-Gold
Sep 1, 1997·Journal of the Neurological Sciences·M B BrombergJ W Albers
Mar 21, 2001·Neuromuscular Disorders : NMD·A EvoliP Tonali
Aug 26, 2006·Nature Clinical Practice. Neurology·John Newsom-Davis
May 22, 2008·Nature Clinical Practice. Neurology·Sivakumar Sathasivam
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Robert M Pascuzzi
Mar 28, 2001·Ryōikibetsu shōkōgun shirīzu·A Suzumura
Jul 20, 2006·International Anesthesiology Clinics·Gilmore N O'Neill
Dec 1, 2004·Journal of Clinical Neuromuscular Disease·Gil I Wolfe, Bella Gross
Sep 23, 2006·The Neurologist·Linda L KusnerHenry J Kaminski
May 22, 2009·International Journal of Rehabilitation Research. Internationale Zeitschrift Für Rehabilitationsforschung. Revue Internationale De Recherches De Réadaptation·Matilde LeonardiRenato Mantegazza
May 21, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C RózsaS Komoly
Apr 21, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G O SkeieUNKNOWN European Federation of Neurological Societies
Sep 29, 2011·Neuroimmunomodulation·Jacqueline Mays, Cherié L Butts
Nov 3, 2006·The Journal of Clinical Investigation·Bianca M Conti-FineHenry J Kaminski
Nov 8, 2007·Orphanet Journal of Rare Diseases·Vern C Juel, Janice M Massey
Apr 1, 2010·Continuum : Lifelong Learning in Neurology·Andrew McKeonSean J Pittock
Aug 25, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·B TackenbergN Sommer
Nov 9, 2010·Clinical Drug Investigation·Corrado Angelini
Aug 6, 2011·Clinical Drug Investigation·Lorenzo Maggi, Renato Mantegazza
Feb 8, 2014·Current Treatment Options in Neurology·Khalid El-SalemSaid S Dahbour
May 8, 2002·The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi·Masayoshi InoueTsutomu Yasumitsu
Oct 19, 2011·Autoimmune Diseases·Nils Erik GilhusJohan A Aarli
Jul 22, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M NagappaA Mahadevan
Jul 30, 2014·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Robert Hülsbrink, Said Hashemolhosseini
Dec 3, 2014·Indian Journal of Ophthalmology·Akshay Gopinathan NairRashmin Anilkumar Gandhi
Feb 13, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·P MaddisonJ Newsom-Davis
May 20, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·Marguerite Hill
Dec 8, 2004·Postgraduate Medical Journal·B R Thanvi, T C N Lo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.